A finished pharmaceutical product adapted for oral release of a physiologically active peptide agent, said product comprising: (a) a therapeutically effective amount of said active peptide selected from the group consisting of calcitonins, parathyroid hormones, H-tyrosine-D-Arginine-phenylalanine -lisin-NH2 and its derivatives, insulin and vasopressin； (b) at least one pharmaceutically acceptable pH reducing agent selected from the group consisting of citric acid, tartaric acid and an acidic salt of an amino acid； and (c) at least one absorption enhancer selected from the group consisting of acylcarnitines, in which the pH reducing agent is present in said finished pharmaceutical product in an amount that, if said product is added to 10 milliliters of a solution of 0.1M aqueous sodium bicarbonate, it would be sufficient to lower the pH of said solution to no more than 5.5, and in which an external surface of said product lacks an acid resistant protective vehicle, provided that said product do not understand a mixture consisting of citric acid, lauroylcarnitine, talc, salmon calcitonin and H-2,6-dimethyltyrosine-D-arginine-phenylalanine-lysine-NH2 ("Dmt-DALDA").Un producto farmacéutico acabado adaptado para liberación oral de un agente peptídico fisiológicamente activo, comprendiendo dicho producto: (a) una cantidad terapéuticamente eficaz de dicho péptido activo seleccionado del grupo que consiste en calcitoninas, hormonas paratiroideas, H-tirosina-D-Arginina-fenilalanina-lisina-NH2 y sus derivados, insulina y vasopresina； (b) al menos un agente reductor del pH farmacéuticamente aceptable seleccionado del grupo que consiste en ácido cítrico, ácido tartárico y una sal ácida de un aminoácido； y (c) al menos un potenciador de la absorción seleccionado del grupo que consiste en acilcarnitinas, en el que el agente reductor del pH está presente en dicho producto farmacéutico acabado en una cantidad que, si dicho producto se añadiera a 10 mililitros de una solución de bic
